OBJECTIVES: To assess the association of site of care (SOC) for rheumatoid arthritis (RA) related biologic infusion with clinical outcomes, health status, work productivity loss, and healthcare resource use. METHODS: In 2009 and 2010, individuals aged ≥18 and reporting an RA diagnosis completed a cross-sectional, self-administered, Internet-based questionnaire.  SOC was categorized as currently receiving infusions of abatacept, infliximab, rituximab, or tocilizumab: in a physician’s office (IOI), a hospital outpatient department (HOPD), or other alternate sites of care (ASOC).  Clinical outcomes included the Health Assessment Questionnaire (HAQ) and severity of morning stiffness, fatigue, and pain, measured as 1=none experienced to 10=severe. Health status was assessed using the SF-36, and work productivity loss was assessed using the Work Productivity and Activity Impairment questionnaire.  Healthcare resource use in the past six months included emergency room visits, hospitalization, and physician visits.  Patient demographics and comorbidities were adjusted using linear regression and negative binomial regression as appropriate. RESULTS: Of 273 infusion patients analyzed, 54.6% (n=149) were categorized as IOI, 11.7% (n=32) HOPD, and 33.7% (n=92) ASOC.  IOI patients were more likely to be female (80.5%) than HOPD and ASOC patients (50.0% and 65.2% respectively, p<0.001).Other demographics and comorbidities were similar across SOC categories.  SOC was not significantly associated with clinical outcomes, health status, work productivity loss, or healthcare resource use with few exceptions.  Compared to IOI patients, HOPD patients had poorer SF-36 role emotional scores (b=-13.54, p=0.022) and ASOC patients had better vitality scores (b=6.67, p=0.006).  Also, ASOC patients had fewer average visits to traditional providers than IOI patients (p=0.011). CONCLUSIONS: With few exceptions, clinical outcomes, health status, work productivity loss, and healthcare resource use are similar regardless of SOC for biologic infusion.  Therefore, other factors may drive choice of SOC, such as convenience for the patient and cost for the patient and payer.